Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $3.1 million.

  • Lyra Therapeutics' Accumulated Expenses fell 3699.28% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 3699.28%. This contributed to the annual value of $4.3 million for FY2024, which is 5362.71% down from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Accumulated Expenses is $3.1 million, which was down 3699.28% from $3.5 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Accumulated Expenses high stood at $11.1 million for Q3 2023, and its period low was $2.0 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $4.9 million (2024), whereas its average is $5.7 million.
  • In the last 5 years, Lyra Therapeutics' Accumulated Expenses skyrocketed by 11248.75% in 2022 and then crashed by 5983.89% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Accumulated Expenses (Quarter) stood at $4.3 million in 2021, then soared by 112.07% to $9.0 million in 2022, then increased by 3.81% to $9.4 million in 2023, then tumbled by 53.63% to $4.3 million in 2024, then dropped by 29.63% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.5 million for Q2 2025, and $4.0 million during Q1 2025.